Cohesin non-CTCF sites carry SA2 and are present at enhancers. To characterize the specific roles of cohesin-SA1 and cohesin-SA2 in chromatin architecture, we selected a primary cell line with comparable levels of the two variant complexes, human mammary Two variant cohesin complexes containing SMC1, SMC3, RAD21 and either SA1 (also known as STAG1) or SA2 (also known as STAG2) are present in all cell types. We report here their genomic distribution and specific contributions to genome organization in human cells. Although both variants are found at CCCTC-binding factor (CTCF) sites, a distinct population of the SA2-containing cohesin complexes (hereafter referred to as cohesin-SA2) localize to enhancers lacking CTCF, are linked to tissue-specific transcription and cannot be replaced by the SA1-containing cohesin complex (cohesin-SA1) when SA2 is absent, a condition that has been observed in several tumors. Downregulation of each of these variants has different consequences for gene expression and genome architecture. Our results suggest that cohesin-SA1 preferentially contributes to the stabilization of topologically associating domain boundaries together with CTCF, whereas cohesin-SA2 promotes cell-type-specific contacts between enhancers and promoters independently of CTCF. Loss of cohesin-SA2 rewires local chromatin contacts and alters gene expression. These findings provide insights into how cohesin mediates chromosome folding and establish a novel framework to address the consequences of mutations in cohesin genes in cancer.
I n addition to mediating sister chromatid cohesion, cohesin contributes to the spatial organization of the genome in chromatin loops and topologically associating domains (TADs) [1] [2] [3] [4] [5] . In vertebrate somatic cells, cohesin complexes carry one of two versions of the SA subunit, namely SA1 or SA2, which are encoded by Stag1 and Stag2, respectively 6 . Studies in human and mouse cells indicate that cohesin-SA1 and cohesin-SA2 are specifically required for telomere and centromere cohesion, respectively 7, 8 . Nevertheless, the cohesion provided by either variant complex is sufficient to allow cell proliferation 9 . Whether the two variants have specific roles in genome organization and gene regulation is unclear, although mouse Stag1null embryos die before birth and show altered cohesin distribution and gene expression 10 . Notably, loss-of-function mutations in the STAG2 gene have been identified in several human cancers, including bladder cancer, Ewing sarcoma and acute myeloid leukemia 11 . Although cohesin-SA1 is sufficient to perform the essential functions of cohesin in STAG2-deficient cancer cells 9 , it may not be able to compensate for other non-essential cohesin-SA2 functions. Consistent with this idea, current evidence suggests that the contribution of cohesin dysfunction to tumorigenesis is not related to cohesion defects or genome instability [12] [13] [14] , but rather to altered gene regulation 15, 16 .
How cohesin affects gene expression remains poorly understood. Analysis of cohesin distribution in mammalian cells shows a large overlap with the sites occupied by the architectural protein CTCF [17] [18] [19] . Cohesin and CTCF are present at the boundaries of TADs, sub-megabase regions identified in whole-genome chromatin-conformation capture (Hi-C) experiments that encompass DNA sequences interacting more frequently with sequences inside than outside the domain 5, 20 . TADs are thought to regulate transcription by facilitating interactions between enhancers and promoters present in the same TAD while preventing interactions between elements from different TADs. Deletion of CTCF sites at TAD boundaries changes local topology and affects gene expression 21, 22 . A model for TAD generation proposes that, after loading, cohesin extrudes DNA to generate progressively longer chromatid loops until it dissociates from chromatin by the action of cohesin release factor WAPL or until it reaches an obstacle, such as CTCF bound to chromatin, where it gets stalled [23] [24] [25] [26] . Cohesin and CTCF are also found inside TADs and contribute to cell-type-specific sub-TAD organization 3 . Moreover, cohesin non-CTCF sites have also been identified in which the complex occupies regions bound by tissuespecific transcription factors or transcriptional regulators such as Mediator [27] [28] [29] . In most of these studies, the potential differences between the two variant cohesin complexes were not addressed. We therefore set out to analyze the distribution of cohesin-SA1 and cohesin-SA2 in nontumor human cells, as well as the consequences of their specific downregulation in gene expression and chromatin architecture. Our results reveal important differences between the behavior of the two complexes in the sites they occupy, the dynamics of their chromatin association, their interaction partners and, as a consequence, their contribution to 3D genome organization.
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NATuRe STRuCTuRAL & MOLeCuLAR BiOLOGy epithelial cells (HMECs; Supplementary Fig. 1 ). We first analyzed the genomic distribution of SMC1, SA1 and SA2 by chromatin immunoprecipitation followed by deep sequencing (ChIP-seq) using custom-made, validated antibodies and high-depth sequencing (about 100 million reads) to ensure whole-genome coverage (Supplementary Dataset 2). Reads were aligned to the reference genome, and peaks were called using MACS2 (false discovery rate (FDR) < 0.01). Overlaps between the peaks obtained in the SA1-specific and SA2-specific immunoprecipitates defined three categories: common, SA2-only and SA1-only positions. Common cohesin positions (42, 475) were occupied by either variant complex and colocalized with CTCF ( Fig. 1a ). They were featured by high cohesin occupancy and similar read density for SA1 and SA2 (Fig. 1b) . In contrast, most of the SA2-only cohesin positions (39, 061) had no or very little CTCF and a lower read density. The fraction of SA1-only positions was small (3, 198) and contained some SA2 and CTCF ( Fig. 1a (lower right) ,b). Analysis of the distribution of these cohesin-binding sites in chromatin states defined by ChromHMM in HMECs 30 revealed that most of the SA2-only cohesin positions (77%) were in enhancers, particularly in active ones (Fig. 1c ). The distribution of the common positions was very different, with only 35% present in enhancers, whereas another 41% were in insulators defined by the sole presence of CTCF. Some SA1-only positions were in insulators (23%) and enhancers (10%), but most were present in a chromatin state that was designated as 'heterochromatin, low signal' 30 . Motif discovery analysis showed that both common and SA1-only positions were significantly enriched for the CTCF-binding motif, whereas SA2-only positions were populated by recognition motifs of several transcription factors other than CTCF ( Supplementary Fig. 2a ).
We validated the findings above in MCF10A cells, a nontumorigenic epithelial breast cell line that, unlike HMECs, can be easily grown and transfected for functional analyses. Common positions had similar average read densities for SA1 and SA2 and overlapped with CTCF ( Fig. 1d,e ). Among the SA2-only positions assigned by peak calling, read distribution heat maps distinguished two clusters ( Fig. 1d ). Although the cohesin positions in both clusters were enriched in SA2, those in cluster 1 contained some SA1 and CTCF (Fig. 1d ), and its distribution among chromatin states was not very different from that of the common and SA1-only positions (Fig. 1f ). The larger cluster 2, in contrast, grouped true SA2-only positionsas in HMECs, these positions lacked CTCF and were enriched in enhancers and depleted in insulators as compared with the common and SA1-only positions (Fig. 1e,f 
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analyses of immunoprecipitates obtained from MCF10A cell extracts with anti-SA1 and anti-SA2 identified several transcriptional regulators that interacted with SA2 and not SA1, including ZMYM2 and YAP1 (Supplementary Dataset 3). ZMYM2 acts as a co-repressor in association with the LSD1-CoREST-HDAC1/2 complex, whereas YAP1 is a co-activator. ChIP-seq analyses for ZMYM2 (this study) and activated YAP1 31 confirmed the presence of SA2, and not SA1 or CTCF, at their binding sites in MCF10A cells ( Supplementary Fig. 2b ). We conclude that cohesin can be found at CTCF sites and non-CTCF sites, and that in the latter case, cohesin-SA2 is the predominant variant. These cohesin-SA2 non-CTCF positions are enriched in cis-regulatory elements co-occupied by transcriptional regulators.
Cohesin-SA2 is linked to tissue-specific transcription. We determined the distribution of cohesin-SA1 and cohesin-SA2 in a third cell line that was of different embryonic origin, human cardiac endothelial cells (HCAECs). Here the number of SA1-only and SA2-only positions was similar ( Fig. 1g ). Read density profile plots for SA1 and SA2 in common positions suggested that ChIP with anti-SA2 had been less efficient in these cells ( Fig. 1h ). We suspect that this has two consequences: (i) SA2-only positions with low cohesin occupancy go undetected, and (ii) a fraction of the positions assigned as SA1 only by peak calling are in fact common positions. In any case, as in the other two cell lines, common and most SA1-only positions overlapped with CTCF, whereas SA2-only positions lacked CTCF. The distribution of SA1-only positions among chromatin states was close to that of the common positions, with a prevalence in insulators, whereas SA2-only positions were enriched in enhancers, as previously described for epithelial cells (Fig. 1i ). We observed that a large fraction of common positions was conserved between the epithelial and endothelial cells, whereas SA1-only and SA2-only positions were not ( Fig. 2a ). Moreover, cohesin-SA2-only sites in HMECs were particularly enriched in super-enhancers defined in the same cell line, which control genes associated with cell identity 32 (Fig. 2b,c) . SA2 signals were enriched relative to SA1 signals in active super-enhancers ( Fig. 2d ), and loss of SA2 at these super-enhancers in HCAECs correlated with decreased expression of their associated genes ( Fig. 2e ).
To further understand the effect of each cohesin variant on gene regulation, we transfected MCF10A cells with siRNAs that targeted the transcripts of the genes encoding SA1 (siSA1) and SA2 (siSA2) and, for comparison, CTCF (siCTCF) and SMC1 (siSMC1). Comparable depletion of SA1 or SA2 left similar amounts of cohesin (SMC1) in the cells (Fig. 3a ). By using a stringent criterion for RNA sequencing (RNA-seq) data analysis, we identified 157 and 716 differentially expressed genes (DEGs) in cells that were treated with siSA1 and siSA2, respectively ( Fig. 3b and Supplementary Datasets 4-6). Of the 630 genes that were deregulated only after SA2 depletion, 445 were not affected by knockdown of CTCF expression, which confirms a CTCF-independent role for SA2 in the control of gene expression. Among the genes that were deregulated in siSA2-treated cells, there were several encoding members of the S100 family of calcium-binding proteins, which are located in a 300-kb-long gene cluster on chromosome 1 ( Fig. 3c (orange dots) and Supplementary Dataset 5). This region contains strong common cohesin peaks, as well as less-prominent cohesin-SA2-only binding sites at the promoters of the deregulated genes ( Fig. 3c ). We used this locus to validate the ChIP-seq data by ChIP-qPCR ( Fig. 3d ) and the RNA-seq data by qRT-PCR ( Fig. 3e ). Other genes whose expression was affected by SA2 downregulation were brainderived neurotrophic factor (BDNF), a known target of CoREST in non-neuronal cells 33 , and those encoding two of the top ten core transcription factors proposed to control cell identity in mammary gland cells 34 , IRX3 and TFAP2C ( Fig. 3f ). Gene set enrichment analyses also revealed aberrant upregulation of pathways specific to the hematopoietic system and the nervous system in MCF10A cells after siSA2 treatment ( Supplementary Fig. 3 ). Taken together with the preferential enrichment of cohesin-SA2 at super-enhancers, these pieces of evidence support a contribution of cohesin-SA2 to tissue-specific gene expression.
Different dynamic behavior of cohesin-SA1 and cohesin-SA2.
ChIP-seq read-density plots of SMC1 distribution around common 
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and cohesin-SA1-only positions produced sharp and narrow profiles in all of the three cell lines analyzed, whereas for SA2-only positions the profiles were broader (Fig. 4a ). These data suggest that the cohesin-SA2 present at these positions is more dynamic. Consistent with this possibility, quantitative ChIP-qPCR analyses showed that cohesin-SA2 at common positions were less likely to associate with WAPL, a factor that dissociates cohesin from chromatin 35 , as compared to those present at the SA2-only positions (Fig. 4b ). Moreover, WAPL removal in HAP1 cells 23 increased SMC1 occupancy more in cohesin non-CTCF sites, which were most likely bound by cohesin-SA2, than in cohesin CTCF sites ( Supplementary Fig. 4 ). There was also more WAPL in anti-SA2 immunoprecipitates than in anti-SA1 immunoprecipitates (highlighted in Supplementary Dataset 3).
To further test our hypothesis that cohesin-SA2 is more dynamic than cohesin-SA1, we performed a salt-extraction experiment. The chromatin fraction of MCF10A cells was treated with 0.25 M or 0.5 M NaCl for 10 or 20 min, and the amount of each variant that remained on the chromatin was assessed by immunoblotting. We found that SA2 was more sensitive to salt than SA1, as seen at all time points in the treatment with the lower salt concentration (Fig. 4c , top and bottom). After treatment with the higher salt concentration, the enhanced sensitivity of SA2 could be seen at the earlier time point (Fig. 4c , middle and bottom). We conclude that the association of cohesin-SA2 with chromatin is less tight, or more dynamic, than the association of cohesin-SA1.
Both cohesin-SA1 and cohesin-SA2 can be found at common cohesin-binding sites. This may be because cells in a population can 
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have either variant complex or because both complexes can coexist at a given position within a cell. Re-ChIP (also known as sequential ChIP) experiments with anti-SA1 and anti-SA2 revealed that at least two independent cohesin rings can coexist in the same genomic position in the same cell ( Fig. 4d,e ). We speculate that stacking at CTCF-bound sites may contribute to stabilize cohesin binding by preventing access of WAPL to cohesin. Alternatively, CTCF itself may stop cohesin progression 36 and at the same time prevent its dissociation by an as yet unclear mechanism.
Cohesin-SA1 cannot occupy SA2-only sites. Next, we asked how cohesin distribution changed after depletion of SA1 or SA2. Calibrated ChIP-seq analyses with anti-SA1 and anti-SA2 were performed in cells that were mock-depleted or depleted of SA1 or SA2. In SA1-depleted cells, there was little cohesin-SA1 left at any position, whereas the presence of cohesin-SA2 increased both at common and SA2-only sites as compared to that in mock-transfected cells, and even at SA1-only sites (Fig. 5 ). It is likely that these SA1only sites, defined based on peak calling ( Fig. 1) , are in fact common 
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positions in which SA2 is immunoprecipitated less efficiently. Of note, cohesin-SA1 could not occupy cohesin-SA2-only sites in SA2depleted cells, and instead it accumulated further at common positions. We conclude that both cohesin-SA1 and cohesin-SA2 can reach common binding sites independently of each other. Thus, in the absence of one variant, the other could, in principle, compensate for its loss at these CTCF-bound sites. In contrast, cohesin-SA1 cannot occupy cohesin-SA2-only positions when SA2 is missing.
Cohesin-SA1 and cohesin-SA2 make different contributions to genome architecture. To address the consequences of SA1 or SA2 depletion on genome architecture, we performed Hi-C experiments in MCF10A cells that were depleted for SA1 or SA2 ( Fig. 6a , Supplementary Fig. 5a,b and Supplementary Dataset 7) . The identity of active (A) and repressive (B) compartments 37 was mostly preserved ( Fig. 6b and Supplementary Fig. 5c ). TAD number increased in 204 TADs after SA1 depletion but decreased in 439 TADs after SA2 depletion (Fig. 6c ). TAD border strength was decreased, particularly in SA1-depleted cells (Fig. 6d ), whereas TAD border conservation was diminished by 25% after SA2 depletion ( Fig. 6e and Supplementary Fig. 5d ). We therefore suggest that some TADs might arise in a CTCF-independent manner and instead depend on the interaction of cohesin-SA2 with different transcriptional regulators. Although we could not test this idea with the current resolution of our Hi-C analyses, it agrees with recent data showing that ~20% of TAD borders are maintained after acute elimination of CTCF in mouse embryonic stem (ES) cells 38 , as well as with high-resolution Hi-C maps from the same cells revealing a set of TAD boundaries featured by the presence of cohesin and active marks but no CTCF 39 . Analysis of genomic interactions as a function of genomic distance further provided evidence for specific contributions of the two cohesin variants to chromatin architecture ( Fig. 6f and Supplementary Fig. 5e ). Loss of SA2 increased mid-range contacts (0.1-1.3 Mb), whereas loss of cohesin-SA1 increased long-range contacts (> 1.4 Mb). These distinct effects were also evident in matrices that represented separately gained and lost interactions for each condition relative to control cells ( Fig. 6g and Supplementary Fig.  6 ). SA1 depletion increased very long-range interactions, most of which were located within the B compartment, whereas mid-range interactions within the A compartment were lost ( Fig. 6g,h (top) ). One possible interpretation of these data is that SA1 depletion results in a more 'relaxed' A compartment, which is compensated by increased compaction of the B compartment. In contrast, SA2 depletion increased inter-TAD mid-range contacts, mostly within the A compartment ( Fig. 6g,h (bottom) ), at least in part owing to loss of TAD borders. SA2 depletion also decreased short-range intra-TAD contacts, which could correspond to enhancer-enhancer or enhancer-promoter interactions, given the prevalence of SA2only positions in these elements. Finally, the specific enrichment of cohesin-SA1-only positions in A-B borders (Fig. 6i ) prompted us to speculate that cohesin-SA1 might have a unique role in modulating A-B compartment identity. However, visual examination of the Hi-C matrices and the resulting eigenvalues used in compartment analyses did not reveal compartment switches in any of the conditions ( Fig. 6b, lower part) .
To interpret our results, we propose that cohesin-SA1 has a more structural role in genome organization, by supporting TAD or sub-TAD formation together with CTCF, whereas cohesin-SA2 is more critical for functional intra-TAD contacts together with transcriptional regulators. In the absence of cohesin-SA1, cohesin-SA2 can still cooperate with CTCF in genome organization, although border strength is decreased and the A compartment is loosened. In the absence of cohesin-SA2, short-range intra-TAD contacts decrease, whereas new contacts are formed between neighboring TADs, and these changes have more noticeable consequences for gene expression.
Discussion
Recent studies in different cellular systems in which cohesin or CTCF depletion was performed have led to the conclusion that TADs and compartments arise independently 38, [40] [41] [42] . TADs would depend on cohesin and CTCF, whereas genomic compartmentalization would rely mostly on epigenetic features regardless of chromatin contacts. Although TAD boundaries are largely invariant across cell types 5 , the specific interactions within TADs may not be 43 . Moreover, results from single-cell Hi-C experiments imply a certain degree of stochasticity in the TAD boundary definition among cells in the population 44, 45 . To our knowledge, our results show for the first time that the two variant cohesin complexes have nonredundant functions in genome organization. After downregulation of one or the other, the changes that we observed were, not unexpectedly, different from those observed after removal of all cohesin [40] [41] [42] . The amount of total cohesin present on chromatin in siSA1-treated and siSA2-treated cells was very similar, whereas the Fig. 1d in control cells and in cells that were treated with siSA1 or siSA2. Two independent replicates were performed for each condition. Read density plots were built by merging the reads from the two replicates.
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relative abundance of each variant changed dramatically, bringing about the changes in cohesin distribution, chromatin contacts and gene expression reported above.
Previous analyses have shown that cohesin colocalizes with transcription factors independently of CTCF and thereby contributes to tissue-specific transcription 29 . Here we show that cohesin-SA2 is the 
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prevalent variant at cohesin non-CTCF sites and confirm that these SA2-only sites tend to be tissue specific and are enriched at enhancers and super-enhancers. Notably, cohesin-SA1 cannot replace cohesin-SA2 at non-CTCF sites. The mechanisms that position SA1-and SA2-containing complexes remain to be identified. The two SA subunits are highly similar, with over 70% sequence identity along the central part of the protein. The homology decreases in the N-and C-terminal regions, and, for instance, SA1 but not SA2 interacts with the telomeric protein TRF1 through its N terminus 46 .
In the same way, SA2 may interact with certain transcriptional regulators through its unique regions. Alternatively, chromatin loops between enhancers and promoters and between CTCF sites may arise by distinct mechanisms, the latter being possibly loop extrusion, and the two SA subunits may be preferentially used for one or the other. In this regard, it is worth mentioning recent in vitro data that show that establishment of DNA-DNA interactions by a cohesin ring already embracing double-stranded DNA requires the second DNA molecule to be single-stranded DNA 47 and that purified SA2 binds single-stranded DNA better than SA1 48 . One could envision cohesin-SA2 interacting with enhancer RNA (eRNA) to stabilize an enhancer-promoter loop 49 . Somatic mutations in STAG2 have been reported in multiple human cancers, most prominently bladder, Ewing sarcoma and myeloid malignancies 11 . The presence of cohesin-SA1 allows STAG2-deficient cancer cells to survive by ensuring sufficient cohesion between the sister chromatids 9 . However, cohesin-SA1 cannot occupy SA2-only sites involved in enhancer-promoter interactions, and, as a consequence, expression of some key genes may be altered. Recent studies have shown that elimination of all chromatin loops mediated by cohesin has little effect on steady-state transcription 40, 42 ; yet, cohesin may be most relevant for transcriptional responses induced after differentiation or lineage commitment 50 , and when deregulated, it may contribute to tumorigenesis, as shown for hematopoietic stem and progenitor cells 51 .
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41594-018-0070-4. Thermo Fisher) supplemented with 20 ng/ml epidermal growth factor (EGF), 0.5 mg/ml hydrocortisone, 100 ng/ml cholera toxin, 10 mg/ml insulin and 5% horse serum.
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Antibodies.
A rabbit polyclonal antibody recognizing human WAPL was generated by using a recombinant C-terminal fragment of the protein (352 amino acids long), cloned by PCR amplification from full-length WAPL cDNA (a gift from T. Hirano (RIKEN, Japan)). A rat monoclonal antibody was raised against the N-terminal region of mouse SA1 and used for western blotting. Additional custom-made antibodies have been previously described for SA1, SA2 and SMC1 8 , for RAD21 52 and for ZMYM2 53 (a gift from H. Yu (UT Southwestern)). Commercial antibodies used included anti-CTCF (clone 07-729; Millipore), anti-tubulin (clone DM1A; Sigma) and anti-histone-H3 (clone ab1791; Abcam).
Quantitative immunoblotting in whole-cell extracts and chromatin fractions.
Cells were collected after trypsin treatment, counted, resuspended in SDS-PAGE loading buffer at 10 7 cells/ml, sonicated and boiled. Equal volumes were separated by SDS-PAGE and analyzed by immunoblotting. Chromatin fractionation was performed as described 54 , and fractions were run on SDS gels alongside increasing amounts of recombinant proteins corresponding to C-terminal fragments of human SA1 and SA2, to estimate the amount of each variant subunit 10 . To assess the strength of chromatin association of the cohesin variants, chromatin fractions were treated with modified buffer A (10 mM HEPES, 1.5 mM MgCl 2 , 0.34 M sucrose, 10% glycerol, 1 mM DTT and protease inhibitors) containing 0.25 M or 0.5 M NaCl for 10, 20 or 30 min on ice. Solubilized proteins were separated from insoluble chromatin by low-speed centrifugation (4 min at 1,700g), and the latter was analyzed by immunoblotting.
Treatment with siRNAs. MCF10A cells were transfected with 50 nM onTARGETplus SMARTpool siRNAs (Dharmacon L-010638, L-021351, L-006833 and L-020165 to target STAG1, STAG2, SMC1 and CTCF, respectively) using DharmaFECT reagent 1. Transfection efficiency was first estimated by qRT-PCR 24 h after transfection, and it typically reached more than 90% downregulation (data not shown). Cells were harvested at 72 h, and protein levels were assessed by immunoblotting.
Chromatin immunoprecipitation followed by sequencing and analysis. ChIP was performed as previously described 34 , with some modifications. Confluent cells were cross-linked with 1% formaldehyde, which was added to the medium for 15 min at room temperature. After a quenching step with 0.125 M glycine, fixed cells were washed twice with PBS containing 1 μ M PMSF and protease inhibitors, pelleted and lysed in lysis buffer (1% SDS, 10 mM EDTA and 50 mM Tris-HCl, pH 8.1) at 2 × 10 7 cells/ml. 10 7 cells (equivalent to 40-50 μ g of chromatin) were used per immunoprecipitation reaction with 25 μ g of antibody. Sonication was performed with a Covaris system (shearing time 30 min, 20% duty cycle, intensity 6, 200 cycles per burst, and 30 s per cycle) in a minimum volume of 2 ml. For calibrated ChIP-seq in siC-, siSA1-and siSA2-treated MCF10A cells, 20% of chromatin from mouse embryonic stem (ES) cells was added to the human chromatin. We doubled the amount of antibody used for the immunoprecipitation reactions to reduce differences on antibody saturation among conditions. ChIP-seq profiles for each antibody were multiplied by the occupancy ratio (OR) = (W m IP h )/ (W h IP m ), where W h and IP h are the number of reads mapped to the human genome from input (W) and immunoprecipitated (IP) fractions, and W m and IP m are reads mapped to the mouse genome from the input and IP fractions 55 . Immunoprecipitated chromatin (6-10 ng, as quantified by fluorometry) was electrophoresed on an agarose gel, and independent sample-specific fractions of 100-200 bp were taken. An adaptor-ligated library was completed by limited-cycle PCR with Illumina PE primers (11-13 cycles). DNA libraries were applied to an Illumina flow cell for cluster generation and sequenced on the Illumina Genome Analyzer IIx (GAIIx). Image analysis was performed with Illumina Real Time Analysis software (RTA1.8).
Alignment of 50-bp-long (76-bp-long for calibrated ChIP samples) sequences to the reference genome (GRCh37/hg19, February 2009) was performed using 'BWA and Bowtie2' 56 under default settings. Duplicates were removed using Picardtools (version 1.60), and peak calling was carried out using MACS2 (version 2.1.1.20160309) after setting the q value (FDR) to 0.05 or 0.01 (SMC1, STAG1 and STAG2 in HMECs) and using the '--extsize' argument with the values obtained in the 'macs2 predictd' step 57 . All comparisons used the input tracks as 'control' and each one of the datasets as 'treatment' .
Common, SA1-only and SA2-only positions were defined using BEDtools v2.26, with a minimum of 1-nt overlap. Common positions were defined in two steps. (i) Overlap between SMC1 and SA1 bed files was performed by using the '-wa -wb' argument, and the positions obtained were concatenated and sorted by using the 'cat' and 'sort -k1,1 -k2,2n' commands. The output was merged by using the 'bedtools merge' function and was considered as one dataset. (ii) This was overlapped with the SA2 dataset as described above. SA1-only and SA2-only positions were those in which SA1 or SA2 did not overlap with each other.
Mean read-density profiles and read-density heat maps for different chromatinbinding proteins were generated with deepTools 2.0 (ref. 58 ) BAM files of processed reads and plotting them around peak summits of SA1-only, SA2-only or common positions.
For motif discovery analysis, whole sequences of cohesin positions were extracted and used for motif enrichment analysis using MEME-ChIP from MEME 59 . Default parameters were used except for the following ones: -ccut 0, -meme-mod anr, -meme-minw: 6, -meme-maxw: 50, -nmeme: 600, -meme-nmotifs: 10, -meme-maxsize: 200,000.
Enrichment of cohesin positions (SA1-only, SA2-only and common) at HMEC and HCAEC chromatin states 30 was defined by using the 'intersect' function from BEDtools utilities (v2.26), with a minimum of 1-nt overlap. The analysis was performed making sure that one position did not belong to two different chromatin states.
To analyze cohesin distribution along super-enhancers, ChIP-seq reads from SA1 and SA2 in HMECs and HCAECs were plotted along HMEC superenhancers 32 using the 'scale-regions' parameter from deepTools to adjust all of the super-enhancers to a predefined size and applying a local regression (LOESS) to smooth the read signals.
Chromatin immunoprecipitation-qPCR and Re-ChIP. ChIP-qPCR on immunoprecipitated chromatin was performed using the SYBR Green PCR Master Mix and an ABI Prism 7900HT instrument (Applied Biosystems). Primers were designed using OligoPerfect Designer (Invitrogen), and reactions were performed in triplicate. Chromosome coordinates of the validated peaks and the corresponding primers are listed in Supplementary Table 1 . The relative amount of each amplified fragment was normalized with respect to the amplification obtained from input DNA using the Δ Δ C t method and is represented as indicated in the corresponding figure legends.
The Re-ChIP experiment was performed with the Re-ChIP-IT kit (cat. no. 53016, Active Motif) according to the manufacturer's protocol. Briefly, MCF10A cells were fixed, lysed and sonicated as described in the ChIP protocol. 50 μ g of chromatin was incubated with 20 μ g of the first antibody (anti-SA1, anti-SA2 or IgG) in the presence of magnetic beads. The beads were washed, and the material was eluted and further incubated with 5 μ g of the second antibody (anti-SA1, anti-SA2, anti-SMC1 or IgG). Eluted chromatin was analyzed by qPCR. 1 ng of the immunoprecipitated chromatin from two conditions-SA2-specific ChIP followed by IgG Re-ChIP and SA2-specific ChIP followed by anti-SA1 Re-ChIP-was used to prepare libraries for Re-ChIP sequencing. Libraries were prepared with 18 PCR cycles. Peaks were called in the SA2-SA1 Re-ChIP experiment after normalization with SA2-IgG Re-ChIP signals.
qRT-PCR and RNA sequencing. cDNAs were prepared with the Superscript II reverse transcriptase (Invitrogen) from total RNA (RNeasy Mini Kit, Qiagen), and qRT-PCR analyses were performed using the SYBR Green PCR Master Mix and an ABI Prism 7900HT instrument (Applied Biosystems). Primers (Supplementary Table 1 ) were designed using OligoPerfect Designer (Invitrogen). Reactions were performed in triplicate. Expression was normalized to that of the endogenous housekeeping gene GAPDH, using the Δ Δ C t method.
For RNA-seq libraries (three replicates for the condition), poly(A) + RNA was purified with the Dynabeads mRNA purification kit (Invitrogen) from DNase I-treated total RNA, randomly fragmented, converted to cDNA and processed through subsequent enzymatic treatments of end repair, dA-tailing, and ligation to adaptors as per Illumina's protocol (TruSeq RNA Sample Preparation Guide; Part 15008136 Rev. A). The adaptor-ligated library was completed by limited-cycle PCR with Illumina PE primers (8 cycles). The resulting purified cDNA library was applied to an Illumina flow cell for cluster generation (TruSeq cluster generation kit v5), and it was sequenced on the Genome Analyzer IIx with SBS TruSeq v5 reagents by following the manufacturer's protocols. Fastq files with 50-nt singleend sequenced reads were quality-checked with FastQC (S. Andrews, 1 nature research | life sciences reporting summary 
Replication
Describe whether the experimental findings were reliably reproduced.
For ChIP-sequencing we have confirmed the distribution of cohesin SA1 and cohesin SA2 by ChIP with an antibody against SMC1. In addition, we have confirmed our results in three different human cell lines (MCF10A, HCAEC and HMEC). For ChIP-seq from control, SA1 and SA2 depleted MCF10A cells, two replicates were performed and sequenced for each antibody.
Several positions (common and SA2-only) were validated by means of ChIP-qPCR (3 technical replicates each).
To assess Wapl/SA2 ratio in different positions by ChIPqPCR we performed at least three experimental replicates (each with three technical replicates).
For re-ChIP experiment we ensured the reliability of the colocalization by reciprocal ChIP of cohesin SA1 and SA2 subunits. Additionally, we included IgG and SMC1 controls.
For Hi-C we performed two replicates (two independent libraries) per condition. Even if in the main figure the analyses were performed combining reads from both replicates, replicates were also analyzed independently and gave similar results ( Supplementary Fig.5 and 6 ).
For proteomic analysis, a single immunoprecipitation experiment per antibody was performed with two technical replicates. Non-immune IgG was used as control.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
n/a
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
n/a
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used. 
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Describe the software used to analyze the data in this study.
All the software used to analyze the data is specified in the online Methods section and in the ChIP-seq report and is publicly available.
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
Custom-made antibodies are available in reasonable amounts upon request
Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species).
Antibodies used for ChIP are described in the ChIP-seq report. A rat monoclonal antibody against SA1 was generated using a 233-aa long Nterminal fragment as antigen and validated for immunoblotting in extracts from WT and SA1 KO MEFs. Commercial cell lines were provided mycoplasm-free. MCF10A cells were periodically tested for mycoplasm (last test was performed right before expansion) with the GEN-PROBE MTC-NI rapid detection system.
d. If any of the cell lines used are listed in the database of commonly misidentified cell lines maintained by ICLAC, provide a scientific rationale for their use.
Not applicable *In the case of calibrated ChIP-seq, number of reads in the right column corresponds to reads obtained after separating reads coming from human chromatin from reads coming from mouse chromatin in the mapping step and after processing. Length of the (single end) reads was 75bp for calibrated ChIPseq and 50 bp for all the rest.
7. Describe the antibodies used for the ChIP-seq experiments.
Home made Cohesin complex antibodies against SMC1, SA1, SA2 and Wapl have been validated using the following strategy:
1. Western blotting in cohesin knocked down cells To assess the specificity of these antibodies we performed western blot in different cell types depleted from each individual subunit as follows:
• SMC1 specificity was tested in MCF10A cells depleted from SMC1 with siRNA on target SMART pool L-006833 (Dharmacon).
• SA1 specificity was tested in MCF10A cells depleted from SA1 with siRNA on target SMART pool L-010638 (Dharmacon) as well as in SA1KO MEFs • SA2 specificity was tested in MCF10A cells depleted from SA2 with siRNA on target SMART pool L-010638 (Dharmacon) and MEFs depleted of SA2 with siGENOME SMARTpool M-057033.
• Wapl specificity was tested in mES cells depleted from Wapl with siRNA siGENOME SMART pool M-047528 (Dharmacon) 2. Immunoprecipitation We successfully performed immunoprecipitation experiments in human and mouse cell lines to assess the ability of the above-mentioned antibodies to recognize and bind its target protein in the context of the cohesin complex. 3. ChIP • We performed SA1 ChIP-seq in SA1 KO MEFs as described (2) . Our data shows a very reduced number of cohesin SA1 peaks (about 600) when compared with those recovered in the wt MEFs (about 26,000).
• To validate the reliability of the positions recovered with cohesin antibodies, we overlap the signals obtained for different subunits. The high degree (typically, higher than 80%) of similarity between SA1 or SA2 and the common subunit SMC1 is an indicator of the efficiency and specificity of the antibodies under discussion.
Zmym2 [a generous gift from H. Yu (UT Southwestern, US)] antibody specificity has been validated by means of immunoprecipitation experiments performed with different members of the Co-REST complex (3) . We performed the following additional validations:
1. Western blotting in knockdown cells: To assess the specificity of the Zmym2 antibody, we performed western blotting in mES cells depleted from Zmym2 protein by means of the siRNA on target SMART pool L-064538 (Dharmacon). 2. ChIP-seq: We confirmed by ChiP-qPCR the ability of Zmym2 antibody to recognize some of the already described Zmym2 binding sites in U2OS cells using a FLAG-tagged version of Zmym2 protein (4).
